# PHOENIX DDR/Anti-PD-L1

Source: https://onco.cc/trials/phoenix/  
OnCo record `phoenix` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PHOENIX, a UK trial from the Institute of Cancer Research, gives women whose triple-negative breast cancer has not responded fully to pre-operative chemotherapy a short course of a DNA-repair drug (olaparib or ceralasertib) or immunotherapy (durvalumab) before surgery, and measures what it does to the tumour, to find which patients could benefit from these drugs after surgery.

## Summary

PHOENIX (NCT03740893) is a non-randomised, biomarker-driven phase 2 window-of-opportunity and adjuvant study for 119 patients with neoadjuvant-treatment-resistant residual triple-negative breast cancer, run by the Institute of Cancer Research with AstraZeneca. Cohorts receive olaparib, the ATR inhibitor ceralasertib (AZD6738) or durvalumab between the end of neoadjuvant chemotherapy and surgery, with paired biopsies; co-primary endpoints are the change in Ki67 proliferation index and in proliferation gene expression for the DNA damage response cohorts, the change in CD8-positive stromal TILs and the interferon-gamma signature for the durvalumab cohort, and plasma ctDNA change for the later cohorts. It opened in October 2019 with primary completion expected in December 2026. No results were indexed in September 2026.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PHOENIX
- Registry id: NCT03740893
- Phase: 2
- Setting: Triple-negative breast cancer with residual disease after neoadjuvant chemotherapy: a pre-surgical window of olaparib, the ATR inhibitor ceralasertib or durvalumab, then post-surgical adjuvant treatment, biomarker-driven, six UK hospitals
- Sponsor: Institute of Cancer Research, United Kingdom, with AstraZeneca
- Enrolled: 119

## Notes

- UK sites (registry, 6): Royal Bournemouth Hospital, King's College Hospital London, Christie Hospital Manchester, Velindre Cancer Centre Cardiff, Guy's and St Thomas' Hospital London, Weston Park Hospital Sheffield.

## Sources

- ClinicalTrials.gov NCT03740893: https://clinicaltrials.gov/study/NCT03740893

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- targets: [ATR](https://onco.cc/targets/atr/), [PARP](https://onco.cc/targets/parp/), [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [Ceralasertib](https://onco.cc/drugs/ceralasertib/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- institutions: [Cancer Research UK](https://onco.cc/institutions/cruk/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Residual cancer burden (RCB)](https://onco.cc/terms/rcb/), [Residual disease after neoadjuvant therapy in triple-negative breast cancer: the decision point](https://onco.cc/terms/tnbc-residual-disease-decision/), [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/), [Tumour-infiltrating lymphocytes (TILs)](https://onco.cc/terms/tils/)
- trials: [KEYNOTE-522](https://onco.cc/trials/keynote-522/), [PARTNER](https://onco.cc/trials/partner/)

---
JSON: https://onco.cc/api/v1/entities/phoenix.json